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Background: Individuals with pre-diabetes (fasting glucose 100–125 mg/dl) are at increased risk of developing
diabetes; 50% of U.S. adults aged ≥65 y had pre-diabetes in 2005–08. Extracts of the leaves of E. guineensis (a
tropical plant producing edible oil), and F. deltoidea (a traditional tea) contain phenolic compounds that have
hypoglycemic effects in vitro and in vivo. Therefore, a study of the efficacy and safety of these leaf extracts was
undertaken.
Methods: Otherwise healthy adults with pre-diabetes (15m/15f; aged 21 to 65 y; BMI ≥25 and < 40 kg/m2) were
assigned to one of 3 groups for 8 weeks: E. guineensis leaf extract 500 mg or 1000 mg or F. deltoidea leaf extract
1000 mg. Assessments at baseline and throughout the study included: fasting plasma glucose, insulin, OGTT, and
HOMA-IR; body weight and waist circumference; vital signs, comprehensive metabolic and lipid panels. Statistical
analyses included paired Student’s t-test and ANCOVA or non-parametric tests when indicated.
Results: E. guineensis intervention for 8 weeks decreased fasting plasma glucose and insulin levels, glucose and
insulin areas under the curve, and insulin resistance, and increased insulin sensitivity. The 500 mg dose of E.
guineensis had a more consistent effect on reducing glycemia than the 1000 mg dose and the insulin findings at
the two dose levels were somewhat inconsistent. Differences in the distribution of baseline insulin levels in the low
and high dose groups may explain some of these observed differences in responses. F. deltoidea leaf extract had
no effect on glycemia variables but both total and LDL cholesterol concentrations were significantly decreased in
this group. There were no significant differences in change of weight; however waist circumference was
significantly lower in the E. guineensis groups after intervention. At baseline and after 8 weeks of intervention, vital
signs and safety lab tests were within normal limits and not significantly different between groups or due to
intervention.
Conclusions: These results suggest that the leaf extracts of E. guineensis and F. deltoidea may have positive effects
on glucose and lipid levels and are safe for use in humans. Further study is required to determine the maximum
effective dosages and the mechanisms of action.
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Table 1 Baseline demographic and anthropometric
characteristics of the subjects
Intervention OPLE-500 OPLE-1000 FICUS TOTAL p=
Enrolled 10 10 10 30 1.0
Completed 9 10 9 28 1.0
Age (y) 44.9±11.4 48.3±13.5 43.5±15. 45.6±13.2 0.72
*Anthropometry
Weight (kg) 87.2±12.4 91.4±19.3 94.1±14.8 91.0±15.4 0.68
Height (cm) 168±8 168±10 169±14 168±11 0.98
BMI (kg/m2) 31.2±4.4 32.1±14.2 33.0±2.2 32.1±3.7 0.59
*Anthropometric variables at the time of screening for study eligibility. Values
are the mean ± SD.
There were no significant differences in any of the demographic or
anthropometric variables at baseline (Student’s t-test for the continuous
variables; Fisher’s Exact Test for the categorical variables).
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In 2010, the World Health Organization reported that
347 million people worldwide had diabetes [1], a number
that was expected to increase to 439 million adults by
2030. The Centers for Disease Control and Prevention
estimated that among U.S. adults aged 65 years and
older, 10.9 million had diabetes in 2010 [2]. The in-
creased proportion of people >65 years of age, especially
in the U.S, may be an important demographic shift influ-
encing diabetes prevalence [3].
Type 2 diabetes accounts for approximately 90% to
95% of all diagnosed cases of diabetes and is character-
ized by fasting plasma glucose concentrations (FPG) ≥
126 mg/dL, 2-hr plasma glucose values (PG) during the
oral glucose tolerance test [OGTT] ≥ 200 mg/dL, or
hemoglobin A1c values (HgbA1c) ≥ 6.5%. In contrast to
the loss of insulin-producing pancreatic beta cells char-
acteristic of type 1 diabetes, type 2 diabetes results from
a progressive insulin secretory defect overlaid on a back-
ground of insulin resistance [4]. Individuals with pre-
diabetes, e.g., those with FPG levels 100–125 mg/dl or
impaired glucose tolerance (IGT, 2-h PG values during
the OGTT of 140 –199 mg/dl), are at increased risk of
developing diabetes, heart disease and stroke. In 2005–
2008, 35% of all U.S. adults aged 20 years or older had
pre-diabetes, including 50% of adults aged 65 years or
older [2]. Extrapolating from these figures to the entire
2010 population suggests that an estimated 79 million
American adults 20 years or older currently have pre-
diabetes [2].
Intensive lifestyle modification, including a healthy
diet, weight loss and physical activity, is the first line of
treatment for pre-diabetes because these steps are more
effective than medication in reducing diabetes risk [5].
There are currently no medications approved by the U.S.
Food and Drug Administration to treat insulin resistance
or pre-diabetes [5]. However, the American Diabetes As-
sociation recommends that metformin should be consid-
ered for use in diabetes prevention, but only for very
high-risk individuals who have a BMI of at least 35 kg/
m2, and are younger than age 60 years [4].
Many alternative therapies — including the anti-
inflammatory salsalate [6], rice-containing resistant
starch [7], aloe vera [8], and polyphenol-containing
compounds such as cinnamon [9] and curcumin [10] —
have been suggested to decrease glycemia in individuals
with pre-diabetes. Because there have been no long-
term trials utilizing these substances, there is no defini-
tive evidence that they are effective; thus, there are no
official recommendations for their use.
The oil palm E. guineensis is grown primarily in the
tropics and equals soybeans as a source of human vege-
table oil consumption [11]. Although the leaf of the oil
palm is a waste product, the alcohol extract of the leafcontains large amounts of phenolic compounds [12,13] that
reportedly promote vascular relaxation and antioxidant ac-
tivity in vitro [14]. In a recent study of streptozotocin
(STZ)-induced hyperglycemic rats, E. guineensis leaf extract
reduced glycemia and lipid oxidation in a dose-dependent
manner, possibly by inhibiting dipeptidyl peptidase-4 (DPP-
4) secretion [15].
In Malaysia, F. deltoidea has traditionally been taken
as tea. Methanol extracts of F. deltoidea plant leaves are
rich sources of polyphenolics, flavonoids and tannins,
the concentrations of which have been found to correl-
ate with antioxidant activity in vitro [16]. Moreover, in
animal studies and cell culture, F. deltoidea leaf extracts
were found to enhance insulin-stimulated glucose up-
take [17].
Due to the increased prevalence of pre-diabetes and
the continuing need for effective pharmacologic treat-
ments of the disorder, the present study was undertaken
to test the safety and efficacy of leaf extracts from E.
guineensis (OPLE) and F. deltoidea (FICUS) in people
with pre-diabetes.Methods
The study design was an 8-week, prospective, random-
ized, and gender-stratified, double-blind, parallel group
clinical trial in otherwise healthy adults with pre-
diabetes. Subjects included 15 male and 15 female sub-
jects, aged 21 to 65 years, with BMI ≥ 25 and 40 < kg/
m2, waist circumference greater than 37 inches (94 cm)
for males and greater than 31 inches (80 cm) for fe-
males, and FPG ≥100 mg/dL (5.6 mmol/L) and ≤ 125
mg/dL (6.9 mmol/L) at the screening visit (Table 1). At
baseline, four weeks and eight weeks, primary efficacy was
assessed by performing an OGTT to measure fasting
plasma glucose and insulin and to calculate HOMA-IR
parameters; secondary efficacy was assessed by measuring
body weight and waist circumference.
Table 2 Composition of the intervention products
Intervention E. guineensis Ficus Placebo
Part of Plant Used Leaves Leaves ————
Active Ingredients Oil palm leaf extract Ficus deltoidea extract ————
Extraction Solvent 50% ethanol, Extraction ratio 10:1 Water Extraction ratio 10:1 ————
Inactive Ingredients Microcrystalline cellulose (100 mg) Microcrystalline cellulose (100 mg) Microcrystalline cellulose (280 mg)
Intervention capsules were prepared by Biotropics Malaysia Berhad.
Table 3 Primary efficacy variables after randomization
and after 8 weeks of intervention
Intervention OPLE-500 OPLE-1000 FICUS
Fasting Plasma Glucose (mg/dL)
*Initial 106±11 103±10 104±14
†Final 99±10 98±8 106±16
Change −7.7±7 −5±7 −1±8
p value for change p=0.02 p=0.06 p=0.61
₤Fasting Plasma Insulin (U/ml)
*Initial 14.4±11.2 8.0±4.3 13.1±5.4
†Final 9.1±5.8 8.6±6.1 11.0±6.0
Change −5.4±7.2 0.6±4.2 −2.1±8.1
p value for change p=0.04 p=0.96 p=0.14
₤Insulin Sensitivity (%)
‡Initial 91 (75) 137 (122) 77 (72)
‡Final 172 (123) 136 (119) 114 (93)
%Change 87±113 7±41 91±25
p value for change p=0.03 p=0.92 p=0.57
₤Insulin Resistance
‡Initial 1.66 (1.34) 0.93 (0.83) 1.50 (1.40)
‡Final 1.04 (0.82) 0.98 (0.84) 1.27 (1.07)
% Change −31%±36 −14%±72 −8%±42
p value for change p=0.055 p=0.92 p=0.65
*Initial values from the baseline OGTT pre-dose sample at the time of
randomization to study. Values are given as the mean ± SD.
†Final values from the baseline OGTT pre-dose sample after 8 weeks of
intervention. Values are given as the mean ± SD.
‡Values are given as the mean (geometric mean).
₤For each continuous variable at each time point, the mean differences in the
variable or in the change in that variable from baseline between the different
products was tested for nominal significance by the one-way analysis of
variance (ANOVA) or by the non-parametric Kruskal-Wallis test if non-normally
distributed. This applied to all of the insulin calculations.
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comprehensive metabolic panel (fasting glucose, BUN,
Cr, AST, ALT, ALP, total protein, albumin, globulin,
GGT, total bilirubin, calcium, chloride, CO2, sodium,
potassium); complete blood count with differential
(RBC, WBC, Hgb, Hct, MCV, MCH, MCHC, RDW,
Platelets, MPV); lipid panel (total cholesterol, TG, HDL,
LDL); blood pressure; heart rate; adverse events; and
subjective remarks. Two weeks after beginning interven-
tion, subjects had a brief visit at which vital signs were
monitored and blood was collected so that the early
safety and efficacy of the products could be determined.
The following test products were provided to the sub-
jects: standardized E. guineensis leaf extract (OPLE; in
one of two doses [500 mg, 1000 mg] or standardized F.
deltoidea leaf extract (FICUS) (one dose [1000 mg]) pro-
duced at Biotropics Malaysia Bhd according to process
mentioned in patent: PCT/MY2011/000008. Each cap-
sule of active product contained either 250 mg of OPLE
or 250 mg of FICUS. Subjects were instructed to take a
total of four capsules per day, two capsules in the morn-
ing and two capsules in the evening, with at least eight
ounces of water, with or without food, starting the day
after being randomized to the study. To maintain the
study blind, two placebo capsules were used for the
OPLE-500 mg arm. The composition of the phytochem-
ical capsules may be found in Table 2. Subjects were re-
quired to bring product bottles to all visits. Compliance
was measured via the pill counting method and recorded
as a percent of prescribed amount for each visit.
Statistical analyses were carried out as follows: for
each continuous variable, the mean change from base-
line to each subsequent time point was tested for nom-
inal significance by the paired Student’s t-test or by the
non-parametric Wilcoxon test if non-normally distrib-
uted. For each continuous variable at each time point,
the mean differences in the variable or in the change in
that variable from baseline between the different prod-
ucts was tested for nominal significance by the one-way
analysis of variance (ANOVA) or by the non-parametric
Kruskal-Wallis test if non-normally distributed. For each
categorical variable, difference in the distribution of cat-
egories between the different product groups was tested
for nominal significance by the Fisher Exact test if pos-
sible, or by the Chi-Square test if necessary. All p-valuesappearing in these summarizations are considered de-
scriptive, not inferential. No final statistical conclusions
are drawn from them. Fisher Exact tests were generated
using the “R” statistical/graphical programming system,
ver.2.15.0 (R Foundation for Statistical Computing, www.
r-project.org). AUC for OGTT parameters was deter-
mined by trapezoidal integration.
This study was approved by the Aspire Institutional

















































Figure 1 Change in primary efficacy variables over 8 weeks of intervention with Elaeis guineensis 500 mg/d (−−-♦—), Elaeis guineensis
1000 mg/d (−−-■—), and Ficus deltoidea 500 mg/d (−−-▲—). Points show the mean value each time point at which the measurement was
taken, with vertical error-bars representing ± 1 SD. a. Fasting plasma glucose (mg/dL). b. Fasting plasma insulin (U/L).
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dures being performed.
Results and discussion
Of the 65 subjects who were phone-screened, 47
reported for in-house screening and 31 were deemed eli-
gible for study. Eligible subjects were randomized in a
gender-stratified manner, each to one of the three study
arms. One subject was lost to follow-up after completing
the randomization visit but an additional subject was en-
rolled and randomized to the same product. One subject
dropped out of the study due to an adverse event, leav-
ing 9 subjects in the OPLE-500 group and 10 each in
the OPLE-1000 and FICUS groups. There were no statisti-
cally significant differences between groups in baseline or
demographic characteristics (Table 1) nor were there gen-
der differences of statistical or clinical significance in any

























Figure 2 Change in areas under the curve (AUC) over 8 weeks of inte
guineensis 1000 mg/d (−−-■—), and Ficus deltoidea 500 mg/d (−−-▲
measurement was taken, with vertical error-bars representing ± 1 SD. c. GluThe primary efficacy variables are shown in Table 3
and Figure 1. Final pre-dose FPG values from the OGTT
were significantly decreased (p=0.015) in the OPLE-500
group after 8 weeks of intervention compared to the
initial pre-dose OGTT FPG values; in the OPLE-1000
group, there was a trend (p=0.06) towards decreased
FPG at 8 weeks. Fasting plasma insulin values in the
OPLE-500 group were significantly decreased at 4 and 8
weeks (p=0.02; p=0.04, respectively; Figure 1b). There
was a non-significant increase in fasting plasma insulin
levels at week 4 (+2.6 ± 4.1; p=0.084) with no change at
week 8 in the OPLE-1000 group. For subjects in the
FICUS group, none of the changes in the primary effi-
cacy variables were found to be significant (Table 3).
However, in contrast to the effects of OPLE, there were
clinically significant changes in lipids after 8 weeks of
intervention in the FICUS group: both total and LDL
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Figure 3 Change in secondary efficacy variables over 8 weeks of intervention with Elaeis guineensis 500 mg/d (−−-♦—), Elaeis
guineensis 1000 mg/d (−−-■—), and Ficus deltoidea 500 mg/d (−−–▲—). Points show the mean value each time point at which the
measurement was taken, with vertical error-bars representing ± 1 SD. a. Body weight (kg) b. Waist Circumference (cm).
Table 4 Secondary efficacy variables at baseline and after
8 weeks of intervention
Intervention OPLE- 500 OPLE-1000 FICUS
Body Weight (kg)
*Baseline 87.2±12.4 91.4±19.3 94.5±14.8
†Final 87.1±14.1 91.9±19.6 95.4±15.7
Change 0.17±2.04 0.58±2.04 0.10±1.53
p value for change p=0.81 p=0.40 p=0.41
Waist Circumference (cm)
*Baseline 104±11 105±11 107±10
†Final 101±10 101±11 107±10
Change −2.8±2.4 −4.2±3.5 −0.4 ±3.5
p value for change p=0.009 p=0.004 p=0.72
*Baseline body weight is the weight at the time of time of screening for
study eligibility.
Values are given as the mean ± SD.
†Final body weight after 8 weeks of intervention. Values are given as the mean
± SD.
For each continuous variable at each time point, the mean differences in the
variable or in the change in that variable from baseline between the different
products was tested for nominal significance by the one-way analysis of
variance (ANOVA) or by the non-parametric Kruskal-Wallis test if
non-normally distributed.
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p=0.012; respectively).
After 8 weeks of intervention, both the glucose and
insulin areas under the curve (AUC) were significantly
decreased in the OPLE-1000 group (−32±44, p=0.046;
−51±68, p=0.006, respectively; Figure 2a and 2b). Using
the homeostatic model assessment estimate of insulin
resistance (HOMA-IR), insulin sensitivity significantly
increased (87±113%, p=0.027) and insulin resistance de-
creased (−31±36, p=0.055) in the OPLE-500 group after
8 weeks of intervention The HOMA-IR model is derived
from fasting glucose and insulin levels with higher levels
representing greater degrees of insulin resistance [18].
The secondary efficacy variables including body weight
and waist circumference were measured at baseline and
4 and 8 weeks after beginning intervention. There were
slight increases in body weight of statistical significance
at week 4 in the OPLE-1000 group (0.96±1.14 kg,
p=0.026) and a trend towards significance in the FICUS
group (0.83 ± 1.25 kg, p = 0.080) (Figure 3a). By week 8,
however, the magnitude of the weight increases had di-
minished and there were no significant differences in
change of weight compared to baseline in any of the
groups (Table 4). There was a non-significant decrease
in waist circumference in all groups by week 4. By week
8, however, waist circumference was significantly lower
in the OPLE- 500 (−2.8 ± 2.4 cm, p = 0.009) and OPLE-
1000 (−4.2 ± 3.5, p = 0.004) groups but not in the FICUS
group (−0.4 ± 3.5, p = 0.72; Figure 3b, Table 4.
Safety variables including vital signs, adverse events
and safety laboratory data were monitored at screening
and weeks 2, 4 and 8. Vital signs were also captured at
randomization. At baseline, vital signs and safety lab
tests were generally within (or nearly within) normal
limits; the few exceptions were not of clinical concern,
not outside of eligibility criteria, and not significantlydifferent between groups. After 8 weeks of intervention,
there were no significant differences in vital signs or
safety lab tests compared to baseline values in any of the
intervention groups (data not shown).
No serious adverse events (SAEs) were observed dur-
ing the course of this study. Eighteen adverse events
(AEs) including upper respiratory tract infection, pha-
ryngitis, sinusitis, acne, hematuria, and tooth abscess
were observed among 15 of the 30 subjects. One of
these events was considered as possibly related to the
study product (intermittent light-headedness). One sub-
ject dropped out of the study due to an AE, although
Kalman et al. Nutrition Journal 2013, 12:36 Page 6 of 7
http://www.nutritionj.com/content/12/1/36the event was not considered possibly or probably re-
lated to the study product.
Compliance percentages were calculated for weeks 1
through 4 and weeks 5 through 8 and averaged to obtain
the overall compliance rate. Overall compliance was
greater than 93% for the 8-week period with no significant
differences among groups. One subject was not suffi-
ciently compliant with the prescribed amount of product
(80% for the first four weeks, and only 50% for the last
four weeks, for an overall compliance rate of only 65%).
As this subject was in the FICUS group, the final per-
protocol population was 28 subjects (OPLE-500 n=9;
OPLE-1000 n=10; FICUS n=9).
Conclusions
This study found a clinically significant, positive effect on
fasting plasma glucose levels in individuals with pre-
diabetes who were treated with the leaf extract of E.
guineensis, a widely grown and utilized tropical palm tree.
In addition, waist circumference, an important indicator
variable in the metabolic syndrome, decreased in both E.
guineensis groups after 8-weeks of intervention. Finally
500 mg and 1000 mg E. guineensis and 500 mg F. deltoidea
were found to be safe by all measures utilized.
The 500 mg low dose of E. guineensis appears to have
had a more consistent effect on reducing glycemia than
the higher 1000 mg dose. Moreover, the insulin findings
at the two dose levels were somewhat inconsistent. Dif-
ferences in the distribution of baseline insulin levels in
the low and high dose groups may explain some of these
observed differences in responses. It is possible that a
larger sample size might result in a less skewed distribu-
tion of baseline insulin levels and would result in more
similar results in the high and low dose groups.
The HOMA-IR result in the low dose E. guineensis
group points to an increase in insulin sensitivity and re-
duction in insulin resistance as potential mechanisms of
action. These findings were not evident in the high dose
group which demonstrated an increase in insulin resist-
ance and a compensatory increase in β-cell function. A
potential mechanism of action for the improvement in
glucose metabolism with E. guineensis involves inhib-
ition of the enzyme dipeptidyl peptidase-4 (DPP-4; [16])
the effect of which is to prevent degradation of gastric
inhibitory polypeptide (GIP), which itself stimulates in-
sulin secretion, suppresses glucagon secretion and slows
gastric emptying. However, as this study did not assess
either DPP-4 activity or the above effects, no comments
can be made about this potential mechanism of action.
E. guineensis is rich in catechins and polyphenols [19].
Prior studies in streptozotocin-induced hyperglycemic
rats showed that E. guineensis improved proteinuria and
reduced oxidative stress levels [20,21]. This suggests a
potential benefit for the pre-diabetic and diabetic states.This animal data, coupled with our findings of enhanced
glycemic control in subjects with pre-diabetes, indicates
that further research in humans is warranted.
Although studies in animals have shown glucose low-
ering effects with F. deltoidea [16,17], this human study
did not support those effects. This study did, however,
demonstrate a lipid lowering effect of great clinical inter-
est. The decreases in total cholesterol and LDL observed
are of statistical and clinical significance and are worthy
of further exploration.
In conclusion, studies of ethanol-derived leaf extracts
of the tropical oil palm E. guineensis and the traditional
tea F. deltoidea offer opportunities for discovering
potential new interventions for pre-diabetes and lipid
abnormalities.
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